PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

Abul Azad; Maryam Arshad; Daniele Generali; Katharina Feldinger; Merel Gijsen; Carla Strina; Mariarosa Cappelletti; Daniele Andreis; Russell Leek; Syed Haider; Pirkko‐Liisa Kellokumpu‐Lehtinen; Ioannis Roxanis; Adrian Llewellyn Harris; Abeer Mahmoud Shaaban; Heikki Joensuu; Anthony Kong

doi:10.1002/cac2.12632

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

Abul Azad, Maryam Arshad, Daniele Generali, Katharina Feldinger, Merel Gijsen, Carla Strina, Mariarosa Cappelletti, Daniele Andreis, Russell Leek, Syed Haider, Pirkko‐Liisa Kellokumpu‐Lehtinen, Ioannis Roxanis, Adrian Llewellyn Harris, Abeer Mahmoud Shaaban, Heikki Joensuu, Anthony Kong^*

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

48 Downloads (Pure)

Original language	English
Journal	Cancer Communications
Early online date	24 Nov 2024
DOIs	https://doi.org/10.1002/cac2.12632
Publication status	E-pub ahead of print - 24 Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cac2.12632Licence: Creative Commons: Attribution (CC BY)

AzadA2024PTPN9Final published version, 774 KBLicence: Creative Commons: Attribution (CC BY)

Cite this

Azad, A., Arshad, M., Generali, D., Feldinger, K., Gijsen, M., Strina, C., Cappelletti, M., Andreis, D., Leek, R., Haider, S., Kellokumpu‐Lehtinen, PL., Roxanis, I., Harris, A. L., Shaaban, A. M., Joensuu, H., & Kong, A. (2024). PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer. Cancer Communications. Advance online publication. https://doi.org/10.1002/cac2.12632

@article{d2add4b3edb14bed8d3f0bb09c02b29b,

title = "PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer",

author = "Abul Azad and Maryam Arshad and Daniele Generali and Katharina Feldinger and Merel Gijsen and Carla Strina and Mariarosa Cappelletti and Daniele Andreis and Russell Leek and Syed Haider and Pirkko‐Liisa Kellokumpu‐Lehtinen and Ioannis Roxanis and Harris, \{Adrian Llewellyn\} and Shaaban, \{Abeer Mahmoud\} and Heikki Joensuu and Anthony Kong",

year = "2024",

month = nov,

day = "24",

doi = "10.1002/cac2.12632",

language = "English",

journal = "Cancer Communications",

issn = "2523-3548",

publisher = "Wiley",

}

Azad, A, Arshad, M, Generali, D, Feldinger, K, Gijsen, M, Strina, C, Cappelletti, M, Andreis, D, Leek, R, Haider, S, Kellokumpu‐Lehtinen, PL, Roxanis, I, Harris, AL, Shaaban, AM, Joensuu, H & Kong, A 2024, 'PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer', Cancer Communications. https://doi.org/10.1002/cac2.12632

TY - JOUR

T1 - PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

AU - Azad, Abul

AU - Arshad, Maryam

AU - Generali, Daniele

AU - Feldinger, Katharina

AU - Gijsen, Merel

AU - Strina, Carla

AU - Cappelletti, Mariarosa

AU - Andreis, Daniele

AU - Leek, Russell

AU - Haider, Syed

AU - Kellokumpu‐Lehtinen, Pirkko‐Liisa

AU - Roxanis, Ioannis

AU - Harris, Adrian Llewellyn

AU - Shaaban, Abeer Mahmoud

AU - Joensuu, Heikki

AU - Kong, Anthony

PY - 2024/11/24

Y1 - 2024/11/24

U2 - 10.1002/cac2.12632

DO - 10.1002/cac2.12632

M3 - Letter

SN - 2523-3548

JO - Cancer Communications

JF - Cancer Communications

ER -